MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Puma Biotechnology Inc

Fermé

SecteurSoins de santé

3.6 0.56

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.49

Max

3.66

Chiffres clés

By Trading Economics

Revenu

-16M

3M

Ventes

-13M

46M

P/E

Moyenne du Secteur

4.597

39.564

Marge bénéficiaire

6.464

Employés

172

EBITDA

-14M

4M

Recommandations

By TipRanks

Recommandations

Vente

Prévisions sur 12 Mois

-16.43% downside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

18M

178M

Ouverture précédente

3.04

Clôture précédente

3.6

Sentiment de l'Actualité

By Acuity

25%

75%

49 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Puma Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juil. 2025, 15:46 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250 Million Private Placement

9 juil. 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 20:26 UTC

Résultats

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 juil. 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 juil. 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 juil. 2025, 17:07 UTC

Market Talk
Acquisitions, Fusions, Rachats

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 juil. 2025, 16:14 UTC

Acquisitions, Fusions, Rachats

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 juil. 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 juil. 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 juil. 2025, 15:31 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250M Private Placement

9 juil. 2025, 15:31 UTC

Market Talk
Acquisitions, Fusions, Rachats

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 juil. 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 juil. 2025, 14:36 UTC

Acquisitions, Fusions, Rachats

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 juil. 2025, 14:31 UTC

Acquisitions, Fusions, Rachats

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 juil. 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 juil. 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparaison

Variation de prix

Puma Biotechnology Inc prévision

Objectif de Prix

By TipRanks

-16.43% baisse

Prévisions sur 12 Mois

Moyen 3 USD  -16.43%

Haut 4 USD

Bas 2 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Vente

2 ratings

0

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

3.07 / 3.075Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

49 / 376Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.